scholarly journals Ron Receptor Tyrosine Kinase Activation Confers Resistance to Tamoxifen in Breast Cancer Cell Lines

Neoplasia ◽  
2010 ◽  
Vol 12 (8) ◽  
pp. 650-658 ◽  
Author(s):  
Rebecca J. McClaine ◽  
Aaron M. Marshal ◽  
Purnima K. Wagh ◽  
Susan E. Waltz
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Receptor Tyrosine Kinase ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Kinase Activation ◽  
Ron Receptor

A gene expression profile indicative of early stage HER2 tyrosine kinase inhibitor response.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11536-e11536
Author(s):  
Fiona O'Neill ◽  
Stephen F. Madden ◽  
Martin Clynes ◽  
Padraig Doolan ◽  
John Crown ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Tyrosine Kinase ◽  
Cell Line ◽  
Expression Pattern ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines

e11536 Background: Lapatinib, afatinib and neratinib are tyrosine kinase inhibitors (TKIs) of HER2 and EGFR growth receptors. A panel of breast cancer cell lines was treated with these agents and gefintib (EGFR inhibitor) and the expression pattern of a specific panel of genes investigated as a potential marker of early drug response. Methods: RNA was extracted from breast cancer cell lines (BT474, SKBR3 and MDAMB453) with differing HER2 expression patterns and sensitivity to lapatinib before and 12hrs after treatment with 1 µM of lapatinib, 150nM of afatinib, 150nM of neratinib or 1µM of gefitinib. Gene expression changes were measured by Taqman RT-PCR and RQ values were determined using the comparative cycle threshold (Ct) method. Results: The expression of RB1CC1, ERBB3, FOXO3a, NR3C1 was directly correlated with the degree of sensitivity of the cell line to lapatinib and was observed to “switch” from up-regulated to down-regulated in the HER2 expressing lapatinib insensitive cell line (MDAMD453). The CCND1 gene (functionally linked to the other four genes) demonstrated an inversely proportional response to drug exposure; showing a trend of strong down-regulation in lapatinib-sensitive lines. A similar expression pattern was observed following the treatment with both neratinib and afatinib. In contrast, gefitinib treatment, resulted in a completely different expression pattern change. Conclusions: In these HER2-expressing cell models, lapatinib, neratinib and afatinib treatment generated a common, characteristic and specific gene expression response, proportionate to the sensitivity of the cell lines to the HER2 inhibitor. Characterisation of changes in these genes shortly after drug treatment may therefore give a valuable predictor of the likely extent and specificity of tumour HER2 inhibitor response in patients, potentially guiding more specific use of these agents.

scholarly journals ABL Tyrosine Kinase Inhibition Variable Effects on the Invasive Properties of Different Triple Negative Breast Cancer Cell Lines

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0118854 ◽  
Author(s):  
Clément Chevalier ◽  
Aude Cannet ◽  
Simon Descamps ◽  
Audrey Sirvent ◽  
Valérie Simon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Abl Tyrosine Kinase

S1994 The Intracellular Tyrosine Kinase PTK6 Plays Distinct Roles in Colon and Breast Cancer Cell Lines

2009 ◽  
Vol 136 (5) ◽  
pp. A-309
Author(s):  
Ansu O. Perekatt ◽  
Jessica Gierut ◽  
Yu Zheng ◽  
Angela L. Tyner
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines
Sign in / Sign up

Export Citation Format

Share Document